Search results
Aug 18, 2023 · Shares of India's Concord Biotech settled 27.2% higher at 942.8 rupees in their trading debut on Friday, valuing the biopharma company at more than 98.63 billion rupees ($1.19 billion) in a dull ...
Concord Biotech Limited is an Indian biotechnology company headquartered in Ahmedabad. The company manufactures fermentation-based biopharmaceutical active pharmaceutical ingredients sold worldwide.
Aug 17, 2023 · Concord Biotech IPO listing will take place on August 18, Friday, and as per latest GMP today, Concord Biotech shares are expected to list at over 16% premium.
Dec 22, 2023 · R&D has played a major role in Concord Biotech’s success. Over the years, Concord has developed several high-quality and cost-competitive products for global markets. Strain improvement and media optimization during fermentation followed by a robust downstream process is key to successfully commercializing the product.
Aug 3, 2023 · About Concord Biotech Concord Biotech (incorporated in 1984) is a leading manufacturer of fermentation-based APIs used in therapeutic areas like immunosuppressants, oncology, anti-infectives and nephrology drugs. Apart from APIs, it also sells formulations (11 per cent of FY23 revenue). Strengths of Concord Biotech
The following disclaimer applies to the Prospectus of Concord Biotech Limited(the “Company”) datedAugust 9, 2023(the “Prospectus”) filed with the Registrar of Companies, Gujarat at Ahmedabad and thereafter with theSecurities and Exchange Board of India (“SEBI”)and the BSE Limited and the National Stock Exchange of India Limited, in relation to the initial public offering of the equity shares of face value of ₹ 1 each (“Equity Shares”) of the Company (“Offer”).
Aug 4, 2023 · Concord Biotech Ltd. IPO The company is a leading India-based biopharma company specializing in fermentation-based APIs for immunosuppressants and oncology. With a significant global market share, the company supply to over 70 countries, including regulated markets.
